Nkarta Future Growth

Future criteria checks 0/6

Nkarta's earnings are forecast to decline at 3.9% per annum while its annual revenue is expected to grow at 72% per year. EPS is expected to grow by 6.7% per annum.

Key information

-3.9%

Earnings growth rate

6.7%

EPS growth rate

Biotechs earnings growth	21.2%
Revenue growth rate	72.0%
Future return on equity	n/a
Analyst coverage	Good
Last updated	26 Mar 2024

Recent future growth updates

Recent updates

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nov 20

Nkarta GAAP EPS of -$0.61

Aug 11

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jun 09

Nkarta: A Promising Natural Killer Cell Play

May 20

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Aug 23

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

May 10

Nkarta gets greenlight from the FDA for NKX019 cancer study

Apr 28

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jan 25

Earnings and Revenue Growth Forecasts

NasdaqGS:NKTX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	11	-151	-167	-111	7
12/31/2025	N/A	-131	-127	-112	8
12/31/2024	N/A	-108	-111	-106	8
12/31/2023	N/A	-118	-114	-86	N/A
9/30/2023	N/A	-122	-127	-70	N/A
6/30/2023	N/A	-125	-123	-65	N/A
3/31/2023	N/A	-119	-110	-59	N/A
12/31/2022	N/A	-114	-104	-57	N/A
9/30/2022	N/A	-104	-80	-67	N/A
6/30/2022	N/A	-98	-78	-71	N/A
3/31/2022	N/A	-93	-77	-72	N/A
12/31/2021	N/A	-86	-73	-68	N/A
9/30/2021	N/A	-81	-68	-63	N/A
6/30/2021	N/A	-72	-62	-57	N/A
3/31/2021	N/A	-102	-56	-50	N/A
12/31/2020	N/A	-91	-51	-44	N/A
9/30/2020	N/A	-84	-44	-37	N/A
6/30/2020	0	-73	-36	-30	N/A
3/31/2020	0	-27	-27	-23	N/A
12/31/2019	0	-21	-20	-18	N/A
12/31/2018	7	0	-6	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NKTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NKTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NKTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NKTX is forecast to have no revenue next year.

High Growth Revenue: NKTX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NKTX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Nkarta Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 7.7% to US$16.00

Price target decreased by 11% to US$17.38

Price target decreased to US$30.36

Price target decreased to US$43.56

Price target decreased to US$44.11

Price target decreased to US$64.71

Recent updates

Nkarta, Inc. has completed a Follow-on Equity Offering in the amount of $240.10001 million.

New minor risk - Shareholder dilution

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta, Inc. has filed a Follow-on Equity Offering in the amount of $240.10001 million.

CEO, President & Director notifies of intention to sell stock

Nkarta: Possible Upside From H1 Update, If Positive

CEO, President & Director recently sold US$85k worth of stock

Price target increased by 7.7% to US$16.00

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Price target decreased by 11% to US$17.38

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New minor risk - Market cap size

Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer

Nkarta, Inc. Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

New minor risk - Share price stability

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Insufficient new directors

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. Promotes David R. Shook to Chief Medical Officer

Price target decreased to US$30.36

Nkarta, Inc. Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

High number of new directors

Nkarta, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CEO, President & Director notifies of intention to sell stock

Nkarta GAAP EPS of -$0.61

Chief Financial & Business Officer exercised options and sold US$71k worth of stock

Nkarta, Inc. Announces Executive Changes

Price target decreased to US$43.56

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Nkarta: A Promising Natural Killer Cell Play

Price target decreased to US$44.11

Nkarta, Inc. Announces Executive Changes

High number of new directors

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

Nkarta, Inc., Annual General Meeting, Jun 08, 2022

Nkarta, Inc. Appoints Angela M. Thedinga to its Board of Directors

Price target decreased to US$64.71

Nkarta, Inc. Presents NKX019 Trial in Progress Poster At the 2021 ASH Annual Meeting and Exposition

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Insider exercised options and sold US$118k worth of stock

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta, Inc.(NasdaqGS:NKTX) dropped from Russell 2500 Growth Index

CEO, President & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Financial & Business Officer notifies of intention to sell stock

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

Nkarta gets greenlight from the FDA for NKX019 cancer study

CEO, President & Director notifies of intention to sell stock

Chief Financial & Business Officer exercised options and sold US$246k worth of stock

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New 90-day high: US$71.96

New 90-day high: US$35.74

New 90-day high: US$35.43

Nkarta Announces Treatment of First Patient in First-In-Human Clinical Trial of Engineered Nkg2d-Based Nk Cell Cancer Immunotherapy Nkx101

Nkarta Announces Presentation of Preclinical Data on NKX019

Nkarta, Inc. Announces Executive Changes

First half earnings released

Nkarta, Inc. has completed an IPO in the amount of $252 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts